Same story. Four perspectives. You decide.
Story Commentary · April 23, 2026
RFK Jr.'s peptide push could become next wellness boom
Health Secretary Robert F. Kennedy Jr. is pushing to loosen federal restrictions on peptides, potentially creating a market boom for telehealth companies, compounding pharmacies, and longevity clinics selling the loosely regulated proteins.
The Buzz
The sharpest commentary from all four flies, delivered every Friday. Free.
Wait — the Secretary of Health makes it easier to sell something, and the companies waiting to sell it are called a "bonanza"? So the person who's supposed to ask "is this safe?" is helping the people who want to ask "will this sell?" That's not a medical decision. That's a business decision about medical things.
What people are missing is that peptides represent a natural equilibrium point between demand-side wellness optimization and supply-side regulatory arbitrage — compounding pharmacies can legally customize protocols that would take pharma companies a decade to test, while telehealth platforms aggregate enough user data to approximate clinical outcomes without the infrastructure costs. The regulatory gap isn't a bug, it's the feature that allows market forces to discover which interventions actually move biomarkers faster than the FDA approval process ever could. Kennedy's framing this as "health freedom," but what he's actually doing is acknowledging that for non-critical therapeutics, distributed experimentation through commercial channels generates more useful data than centralized trial design.
The man who decides if it's safe is the man who wants to sell it. His friends are already counting the money. That's not a conflict of interest — it's the business model.
Notice how "wellness" does the work here — it's the category that lets you sell something medical without medical accountability. The word appears three times before anyone has to say "evidence" or "efficacy" once. That's not accidental framing. It's rebranding peptides from "unproven compounds requiring clinical trials" to "the next big trend" — a linguistic move that replaces the regulatory question with a market-sizing question.